FGF1 is a signal peptide-less nonclassically released growth factor that is involved in angiogenesis, tissue repair, inflammation, and carcinogenesis. The effects of nonclassical FGF export in vivo are not sufficiently studied. We produced transgenic mice expressing FGF1 in endothelial cells (EC), which allowed the detection of FGF1 export to the vasculature, and studied the efficiency of postischemic kidney repair in these animals. Although FGF1 transgenic mice had a normal phenotype with unperturbed kidney structure, they showed a severely inhibited kidney repair after unilateral ischemia/reperfusion. This was manifested by a strong decrease of postischemic kidney size and weight, whereas the undamaged contralateral kidney exhibited an enhanced compensatory size increase. In addition, the postischemic kidneys of transgenic mice were characterized by hyperplasia of interstitial cells, paucity of epithelial tubular structures, increase of the areas occupied by connective tissue, and neutrophil and macrophage infiltration. The continuous treatment of transgenic mice with the cell membrane stabilizer, taurine, inhibited nonclassical FGF1 export and significantly rescued postischemic kidney repair. It was also found that similar to EC, the transgenic expression of FGF1 in monocytes and macrophages suppresses kidney repair. We suggest that nonclassical export may be used as a target for the treatment of pathologies involving signal peptide-less FGFs.
References
[1]
Itoh N, Ornitz DM (2008) Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237: 18–27.
[2]
Yun YR, Won JE, Jeon E, Lee S, Kang W, et al. (2010) Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng 2010: 218142.
[3]
Dorey K, Amaya E (2010) FGF signalling: diverse roles during early vertebrate embryogenesis. Development 137: 3731–3742.
[4]
Korc M, Friesel RE (2009) The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 9: 639–651.
[5]
Jackson A, Friedman S, Zhan X, Engleka KA, Forough R, et al. (1992) Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 cells. Proc Natl Acad Sci U S A 89: 10691–10695.
[6]
Mignatti P, Morimoto T, Rifkin DB (1992) Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol 151: 81–93.
[7]
Prudovsky I, Tarantini F, Landriscina M, Neivandt D, Soldi R, et al. (2008) Secretion without Golgi. J Cell Biochem 103: 1327–1343.
[8]
Nickel W, Rabouille C (2009) Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 10: 148–155.
[9]
Cauchi J, Alcorn D, Cancilla B, Key B, Berka JL, et al. (1996) Light-microscopic immunolocalization of fibroblast growth factor-1 and -2 in adult rat kidney. Cell Tissue Res 285: 179–187.
[10]
Rossini M, Cheunsuchon B, Donnert E, Ma LJ, Thomas JW, et al. (2005) Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int 68: 2621–2628.
[11]
Cancilla B, Davies A, Cauchi JA, Risbridger GP, Bertram JF (2001) Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int 60: 147–155.
[12]
Ichimura T, Maier JA, Maciag T, Zhang G, Stevens JL (1995) FGF-1 in normal and regenerating kidney: expression in mononuclear, interstitial, and regenerating epithelial cells. Am J Physiol 269: F653–662.
[13]
Qiao J, Bush KT, Steer DL, Stuart RO, Sakurai H, et al. (2001) Multiple fibroblast growth factors support growth of the ureteric bud but have different effects on branching morphogenesis. Mech Dev 109: 123–135.
[14]
Brown AC, Adams D, de Caestecker M, Yang X, Friesel R, et al. (2011) FGF/EGF signaling regulates the renewal of early nephron progenitors during embryonic development. Development 138: 5099–5112.
[15]
Zakrzewska M, Marcinkowska E, Wiedlocha A (2008) FGF-1: from biology through engineering to potential medical applications. Crit Rev Clin Lab Sci 45: 91–135.
[16]
Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, et al. (1996) Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 120: 182–188.
[17]
Schumacher B, Pecher P, von Specht BU, Stegmann T (1998) Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97: 645–650.
[18]
Buehler A, Martire A, Strohm C, Wolfram S, Fernandez B, et al. (2002) Angiogenesis-independent cardioprotection in FGF-1 transgenic mice. Cardiovasc Res 55: 768–777.
[19]
Engel FB, Hsieh PC, Lee RT, Keating MT (2006) FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci U S A 103: 15546–15551.
[20]
Hershey JC, Corcoran HA, Baskin EP, Gilberto DB, Mao X, et al. (2003) Enhanced hindlimb collateralization induced by acidic fibroblast growth factor is dependent upon femoral artery extraction. Cardiovasc Res 59: 997–1005.
[21]
Villanueva S, Cespedes C, Gonzalez AA, Roessler E, Vio CP (2008) Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 294: R819–828.
[22]
Villanueva S, Cespedes C, Gonzalez A, Vio CP (2006) bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 291: R1677–1687.
[23]
Khurana R, Simons M (2003) Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med 13: 116–122.
[24]
Kirov A, Al-Hashimi H, Solomon P, Mazur C, Thorpe PE, et al. (2012) Phosphatidylserine externalization and membrane blebbing are involved in the nonclassical export of FGF1. J Cell Biochem 113: 956–966.
[25]
Tomaszewski M, Charchar FJ, Lynch MD, Padmanabhan S, Wang WY, et al. (2007) Fibroblast growth factor 1 gene and hypertension: from the quantitative trait locus to positional analysis. Circulation 116: 1915–1924.
[26]
Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, et al. (2009) Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119: 512–523.
[27]
Hutley L, Shurety W, Newell F, McGeary R, Pelton N, et al. (2004) Fibroblast growth factor 1: a key regulator of human adipogenesis. Diabetes 53: 3097–3106.
[28]
Erzurum VZ, Bian JF, Husak VA, Ellinger J, Xue L, et al. (2003) R136K fibroblast growth factor-1 mutant induces heparin-independent migration of endothelial cells through fibrin glue. J Vasc Surg 37: 1075–1081.
[29]
Duarte M, Kolev V, Soldi R, Kirov A, Graziani I, et al. (2006) Thrombin induces rapid PAR1-mediated non-classical FGF1 release. Biochem Biophys Res Commun 350: 604–609.
[30]
Yan C, Lian X, Li Y, Dai Y, White A, et al. (2006) Macrophage-specific expression of human lysosomal acid lipase corrects inflammation and pathogenic phenotypes in lal？/？ mice. Am J Pathol 169: 916–926.
[31]
Brancato SK, Albina JE (2011) Wound macrophages as key regulators of repair: origin, phenotype, and function. Am J Pathol 178: 19–25.
[32]
Kasama T, Miwa Y, Isozaki T, Odai T, Adachi M, et al. (2005) Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 4: 273–279.
[33]
Chatterjee PK (2007) Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 376: 1–43.
[34]
Chesney RW, Han X, Patters AB (2010) Taurine and the renal system. J Biomed Sci 17: Suppl 1S4.
[35]
Tarantini F, Gamble S, Jackson A, Maciag T (1995) The cysteine residue responsible for the release of fibroblast growth factor-1 residues in a domain independent of the domain for phosphatidylserine binding. J Biol Chem 270: 29039–29042.
[36]
Graziani I, Bagala C, Duarte M, Soldi R, Kolev V, et al. (2006) Release of FGF1 and p40 synaptotagmin 1 correlates with their membrane destabilizing ability. Biochem Biophys Res Commun.
[37]
Ku PT, D’Amore PA (1995) Regulation of basic fibroblast growth factor (bFGF) gene and protein expression following its release from sublethally injured endothelial cells. J Cell Biochem 58: 328–343.
[38]
Matsunaga S, Okigaki M, Takeda M, Matsui A, Honsho S, et al. (2009) Endothelium-targeted overexpression of constitutively active FGF receptor induces cardioprotection in mice myocardial infarction. J Mol Cell Cardiol 46: 663–673.
[39]
Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, et al. (2009) A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114: 901–914.
[40]
Grgic I, Duffield JS, Humphreys BD (2012) The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 27: 183–193.
[41]
Strutz F, Neilson EG (2003) New insights into mechanisms of fibrosis in immune renal injury. Springer Semin Immunopathol 24: 459–476.
[42]
Braun N, Reimold F, Biegger D, Fritz P, Kimmel M, et al. (2009) Fibrogenic growth factors in encapsulating peritoneal sclerosis. Nephron Clin Pract 113: c88–95.
[43]
Gerber SD, Steinberg F, Beyeler M, Villiger PM, Trueb B (2009) The murine Fgfrl1 receptor is essential for the development of the metanephric kidney. Dev Biol 335: 106–119.
[44]
Yu C, Wang F, Jin C, Huang X, Miller DL, et al. (2003) Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol 163: 1653–1662.
[45]
Meij JT, Sheikh F, Jimenez SK, Nickerson PW, Kardami E, et al. (2002) Exacerbation of myocardial injury in transgenic mice overexpressing FGF-2 is T cell dependent. Am J Physiol Heart Circ Physiol 282: H547–555.
[46]
Fallahzadeh MK, Namazi MR, Gupta RC (2010) Taurine: a potential novel addition to the anti-systemic sclerosis weaponry. Arch Med Res 41: 59–61.
[47]
Guz G, Oz E, Lortlar N, Ulusu NN, Nurlu N, et al. (2007) The effect of taurine on renal ischemia/reperfusion injury. Amino Acids 32: 405–411.
[48]
Lasky JA, Ortiz LA (2001) Antifibrotic therapy for the treatment of pulmonary fibrosis. Am J Med Sci 322: 213–221.
[49]
Li L, Okusa MD (2010) Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol 30: 268–277.
